Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Aspirin, Acetaminophen, and Caffeine	299
Overall Study	STARTED	Sumatriptan (100 mg)	304
Overall Study	STARTED	Placebo	149
Overall Study	Safety Population	Aspirin, Acetaminophen, and Caffeine	266
Overall Study	Safety Population	Sumatriptan (100 mg)	271
Overall Study	Safety Population	Placebo	133
Overall Study	ITT Population	Aspirin, Acetaminophen, and Caffeine	256
Overall Study	ITT Population	Sumatriptan (100 mg)	261
Overall Study	ITT Population	Placebo	125
Overall Study	COMPLETED	Aspirin, Acetaminophen, and Caffeine	284
Overall Study	COMPLETED	Sumatriptan (100 mg)	290
Overall Study	COMPLETED	Placebo	145
Overall Study	NOT COMPLETED	Aspirin, Acetaminophen, and Caffeine	15
Overall Study	NOT COMPLETED	Sumatriptan (100 mg)	14
Overall Study	NOT COMPLETED	Placebo	4

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01248468/flow